Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072344 · ClinicalTrials.gov registry record · Phase 3
Long Term Chamomile Therapy for Anxiety
A Phase 3 study of Generalized Anxiety Disorder, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT01072344 is a Phase 3 study of Generalized Anxiety Disorder that has completed, run by University of Pennsylvania. The registered enrollment target is 180 participants, below the 211-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01072344, a Phase 3 study of Generalized Anxiety Disorder, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
Prior research has shown that chamomile may be an effective, short-term anti-anxiety treatment. This study will examine the initial and long-term benefits of chamomile extract therapy for the prevention of recurrent anxiety disorder.
Conditions Studied
Interventions
- DRUG Chamomile (Matricaria recutita)
Study Locations (1)
Pennsylvania
- Depression Research Unit - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2010-02 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072344
The ClinicalTrials.gov registry entry for NCT01072344 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (15% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 1 intervention - of which Chamomile (Matricaria recutita) is the first listed.
NCT01072344 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01072344 about?
NCT01072344 is a clinical study titled "Long Term Chamomile Therapy for Anxiety". Prior research has shown that chamomile may be an effective, short-term anti-anxiety treatment. This study will examine the initial and long-term benefits of chamomile extract therapy for the prevention of recurrent anxiety disorder.
What is the current status of trial NCT01072344?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2010-02. Estimated completion is 2015-06.
What conditions does trial NCT01072344 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT01072344?
The interventions under investigation include: Chamomile (Matricaria recutita) (DRUG).
Who is sponsoring clinical trial NCT01072344?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01072344 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
RECRUITING · Phase 3
-
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
RECRUITING · Phase 3
-
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.